BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37552122)

  • 1. T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia.
    Montironi C; Jacobs CF; Cretenet G; Peters FS; Schomakers BV; van Weeghel M; Kater AP; Simon-Molas H; Eldering E
    Blood Adv; 2023 Nov; 7(21):6540-6552. PubMed ID: 37552122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells.
    van Bruggen JAC; van der Windt GJW; Hoogendoorn M; Dubois J; Kater AP; Peters FS
    Blood Adv; 2022 Jul; 6(14):4185-4195. PubMed ID: 35580333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells.
    Romano C; De Fanis U; Sellitto A; Dalla Mora L; Chiurazzi F; Giunta R; Rotoli B; Lucivero G
    Leuk Lymphoma; 2003 Nov; 44(11):1963-71. PubMed ID: 14738151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of chronic lymphocytic leukemia cells to chemotherapeutic drugs ex vivo depends on expression status of cell surface receptors.
    Shcherbina V; Gordiienko I; Shlapatska L; Ivanivska T; Sidorenko S
    Exp Oncol; 2020 Mar; 42(1):16-24. PubMed ID: 32231196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib treatment improves T cell number and function in CLL patients.
    Long M; Beckwith K; Do P; Mundy BL; Gordon A; Lehman AM; Maddocks KJ; Cheney C; Jones JA; Flynn JM; Andritsos LA; Awan F; Fraietta JA; June CH; Maus MV; Woyach JA; Caligiuri MA; Johnson AJ; Muthusamy N; Byrd JC
    J Clin Invest; 2017 Aug; 127(8):3052-3064. PubMed ID: 28714866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia.
    Harr MW; Caimi PF; McColl KS; Zhong F; Patel SN; Barr PM; Distelhorst CW
    Cell Death Differ; 2010 Sep; 17(9):1381-91. PubMed ID: 20300113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling.
    Lorenzo-Herrero S; Sordo-Bahamonde C; Bretones G; Payer ÁR; González-Rodríguez AP; González-García E; Pérez-Escuredo J; Villa-Álvarez M; Núñez LE; Morís F; Gonzalez S; López-Soto A
    Front Immunol; 2019; 10():2455. PubMed ID: 31681329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients.
    Karabon L; Partyka A; Ciszak L; Pawlak-Adamska E; Tomkiewicz A; Bojarska-Junak A; Roliński J; Wołowiec D; Wrobel T; Frydecka I; Kosmaczewska A
    J Immunol Res; 2020; 2020():6545921. PubMed ID: 32775467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia.
    Jitschin R; Hofmann AD; Bruns H; Giessl A; Bricks J; Berger J; Saul D; Eckart MJ; Mackensen A; Mougiakakos D
    Blood; 2014 Apr; 123(17):2663-72. PubMed ID: 24553174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chrysin induces apoptosis in peripheral blood lymphocytes isolated from human chronic lymphocytic leukemia.
    Zaric M; Mitrovic M; Nikolic I; Baskic D; Popovic S; Djurdjevic P; Milosavljevic Z; Zelen I
    Anticancer Agents Med Chem; 2015; 15(2):189-95. PubMed ID: 25257897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
    Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
    Front Immunol; 2020; 11():590072. PubMed ID: 33329575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.
    de Weerdt I; Hofland T; de Boer R; Dobber JA; Dubois J; van Nieuwenhuize D; Mobasher M; de Boer F; Hoogendoorn M; Velders GA; van der Klift M; Remmerswaal EBM; Bemelman FJ; Niemann CU; Kersting S; Levin MD; Eldering E; Tonino SH; Kater AP
    Blood Adv; 2019 Sep; 3(17):2642-2652. PubMed ID: 31506282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells.
    Morande PE; Zanetti SR; Borge M; Nannini P; Jancic C; Bezares RF; Bitsmans A; González M; Rodríguez AL; Galmarini CM; Gamberale R; Giordano M
    Invest New Drugs; 2012 Oct; 30(5):1830-40. PubMed ID: 21887502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.
    Martens AWJ; Janssen SR; Derks IAM; Adams Iii HC; Izhak L; van Kampen R; Tonino SH; Eldering E; van der Windt GJW; Kater AP
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-25 Impact on Malignant B Cells Survival and T Cells Activation in Chronic Lymphocytic Leukemia.
    Pashei M; Ghahremanfard F; Manouchehri Doulabi E; Hemmati M; Pak F; Kokhaei P
    Iran J Allergy Asthma Immunol; 2023 Jun; 22(3):299-311. PubMed ID: 37524666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells.
    de Frias M; Iglesias-Serret D; Cosialls AM; Coll-Mulet L; Santidrián AF; González-Gironès DM; de la Banda E; Pons G; Gil J
    Haematologica; 2009 Dec; 94(12):1698-707. PubMed ID: 19815839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.
    Kashyap MK; Amaya-Chanaga CI; Kumar D; Simmons B; Huser N; Gu Y; Hallin M; Lindquist K; Yafawi R; Choi MY; Amine AA; Rassenti LZ; Zhang C; Liu SH; Smeal T; Fantin VR; Kipps TJ; Pernasetti F; Castro JE
    J Hematol Oncol; 2017 May; 10(1):112. PubMed ID: 28526063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutathione depletion in chronic lymphocytic leukemia B lymphocytes.
    Silber R; Farber CM; Papadopoulos E; Nevrla D; Liebes L; Bruck M; Brown R; Canellakis ZN
    Blood; 1992 Oct; 80(8):2038-43. PubMed ID: 1356514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCγ1 activation: evidence from mice and humans.
    Martinez-Torres AC; Quiney C; Attout T; Boullet H; Herbi L; Vela L; Barbier S; Chateau D; Chapiro E; Nguyen-Khac F; Davi F; Le Garff-Tavernier M; Moumné R; Sarfati M; Karoyan P; Merle-Béral H; Launay P; Susin SA
    PLoS Med; 2015 Mar; 12(3):e1001796. PubMed ID: 25734483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.